CD22 CAR-T Therapy Shows Results in Leukemia, Study Shows, But Could a Dual CAR-T Deliver the One-Two Punch to Avoid Relapse?
The Parker Institute for Cancer Immunotherapy enables real collaboration, accelerating ambitious research to deliver new immunotherapies engineered to save lives.
World-renowned experts from leading cancer centers are at the forefront of our research.
Open in Twitter Parker Institute @parkerici CD19 CAR-T cell therapy expands to treat refractory lymphoma. One of the fascinating @NEJM papers led by PICI's Car… https://t.co/9T4x0TuKw9 22 hours ago
Open in Twitter Parker Institute @parkerici RT @theNCI: Treating cancer with CAR T-cells is like giving patients a “living drug.” https://t.co/jJFsDiRiHr #immunotherapy #CARTcells #Im… 2 days ago